ASX - By Stock
|
PAA |
Re:
PharmAust media thread
|
|
enkayess
|
304 |
71K |
16 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
304
|
71K
|
16
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
enkayess
|
178 |
27K |
4 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
178
|
27K
|
4
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
971 |
226K |
13 |
13/03/24 |
13/03/24 |
ASX - By Stock
|
971
|
226K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
971 |
226K |
5 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
971
|
226K
|
5
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
enkayess
|
971 |
226K |
9 |
02/03/24 |
02/03/24 |
ASX - By Stock
|
971
|
226K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
enkayess
|
323 |
71K |
27 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
323
|
71K
|
27
|
|
ASX - By Stock
|
MGT Iron Ore |
Re:
MGT $ 1.00 TARGET PRICE 2024
|
|
enkayess
|
72 |
22K |
4 |
05/02/24 |
05/02/24 |
ASX - By Stock
|
72
|
22K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: FDA Provides Clear Feedback for ODD Approval
|
|
enkayess
|
323 |
71K |
21 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
323
|
71K
|
21
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
102K |
25 |
24/01/24 |
24/01/24 |
ASX - By Stock
|
430
|
102K
|
25
|
|
ASX - By Stock
|
PAA |
Re:
Sparks Valuation Pharmaust
|
|
enkayess
|
111 |
33K |
14 |
19/01/24 |
19/01/24 |
ASX - By Stock
|
111
|
33K
|
14
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
enkayess
|
98 |
22K |
19 |
18/01/24 |
18/01/24 |
ASX - By Stock
|
98
|
22K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
enkayess
|
98 |
22K |
32 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
98
|
22K
|
32
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.0M |
7 |
12/01/24 |
12/01/24 |
Charts
|
13K
|
5.0M
|
7
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Change in substantial holding
|
|
enkayess
|
13 |
4.9K |
0 |
29/12/23 |
29/12/23 |
ASX - By Stock
|
13
|
4.9K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
102K |
13 |
04/12/23 |
04/12/23 |
ASX - By Stock
|
430
|
102K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
102K |
5 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
430
|
102K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PAA completes Phase 1 and files for Orphan Drug Designation
|
|
enkayess
|
430 |
102K |
34 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
430
|
102K
|
34
|
|
ASX - By Stock
|
MGT |
Re:
Ann: Appendix 3Y - Change of Directors' Interest Notice x 6
|
|
enkayess
|
4 |
952 |
6 |
23/11/23 |
23/11/23 |
ASX - By Stock
|
4
|
952
|
6
|
|
ASX - By Stock
|
PAA Biotech |
Re:
Full takeover versus multiple deals?
|
|
enkayess
|
76 |
12K |
11 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
76
|
12K
|
11
|
|
ASX - By Stock
|
PAA Biotech |
Re:
FDA Application for Orphan Drug Designation , PAA, MPL
|
|
enkayess
|
355 |
67K |
14 |
14/11/23 |
14/11/23 |
ASX - By Stock
|
355
|
67K
|
14
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.0M |
1 |
10/11/23 |
10/11/23 |
Charts
|
13K
|
5.0M
|
1
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.0M |
1 |
10/11/23 |
10/11/23 |
Charts
|
13K
|
5.0M
|
1
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust to present at Emerging ASX Gems Conference
|
|
enkayess
|
82 |
16K |
16 |
08/11/23 |
08/11/23 |
ASX - By Stock
|
82
|
16K
|
16
|
|
ASX - By Stock
|
MGT |
Re:
Ann: Razorback Iron Ore Project Update
|
|
enkayess
|
133 |
36K |
0 |
06/09/23 |
06/09/23 |
ASX - By Stock
|
133
|
36K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Who wants a Zoom Meeting with Management
|
|
enkayess
|
28 |
4.9K |
3 |
23/08/23 |
23/08/23 |
ASX - By Stock
|
28
|
4.9K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Trading Halt
|
|
enkayess
|
78 |
20K |
16 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
78
|
20K
|
16
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Investor Education Update & Webinar
|
|
enkayess
|
2 |
938 |
0 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
2
|
938
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
79K |
5 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
396
|
79K
|
5
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
79K |
9 |
08/08/23 |
08/08/23 |
ASX - By Stock
|
396
|
79K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
enkayess
|
218 |
48K |
9 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
218
|
48K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Biomarkers and Pharmacodynamics Results
|
|
enkayess
|
396 |
79K |
6 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
396
|
79K
|
6
|
|
ASX - By Stock
|
BDX |
Re:
Ann: Breakthrough Results a Major Step Towards Commercialisation
|
|
enkayess
|
74 |
26K |
3 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
74
|
26K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
enkayess
|
218 |
48K |
3 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
48K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Epichem enters voluntary liquidation
|
|
enkayess
|
218 |
48K |
8 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
218
|
48K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
enkayess
|
200 |
39K |
10 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
200
|
39K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Results show MPL suppresses biomarkers associated with MND
|
|
enkayess
|
200 |
39K |
12 |
14/07/23 |
14/07/23 |
ASX - By Stock
|
200
|
39K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
|
enkayess
|
165 |
33K |
13 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
165
|
33K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
enkayess
|
151 |
29K |
8 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
151
|
29K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Successfully Completes Second Patient Cohort
|
|
enkayess
|
52 |
11K |
12 |
11/05/23 |
11/05/23 |
ASX - By Stock
|
52
|
11K
|
12
|
|
ASX - By Stock
|
PAA |
Re:
Patents
|
|
enkayess
|
12 |
2.0K |
11 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
12
|
2.0K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Patents
|
|
enkayess
|
12 |
2.0K |
9 |
10/05/23 |
10/05/23 |
ASX - By Stock
|
12
|
2.0K
|
9
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
enkayess
|
121 |
25K |
13 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
121
|
25K
|
13
|
|
ASX - By Stock
|
BDX |
Re:
Ann: BCAL Opens Development & Clinical Service Laboratory
|
|
enkayess
|
10 |
3.6K |
3 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
10
|
3.6K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Multi Blockbuster Share??
|
|
enkayess
|
73 |
16K |
15 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
73
|
16K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Multi Blockbuster Share??
|
|
enkayess
|
73 |
16K |
4 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
73
|
16K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MND Trial Completes Enrolment of Cohort 2
|
|
enkayess
|
104 |
26K |
19 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
104
|
26K
|
19
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Stable Patient in MND trial reaches 6-months on MPL
|
|
enkayess
|
70 |
15K |
14 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
70
|
15K
|
14
|
|
ASX - By Stock
|
MGT |
Re:
Achieved Goals, Future Goals & Timeline
|
|
enkayess
|
34 |
14K |
15 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
34
|
14K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Interim analysis recommended in MND trial
|
|
enkayess
|
71 |
18K |
13 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
71
|
18K
|
13
|
|
Charts
|
MGT |
Re:
MGT share price
|
|
enkayess
|
13K |
5.0M |
15 |
01/03/23 |
01/03/23 |
Charts
|
13K
|
5.0M
|
15
|
|